Latest Articles

Publication Date
Natural Pregnancy Following Oocyte Retrieval in a Luteal-Phase Progestin-Primed Ovarian Stimulation (PPOS) Protocol With Concurrent Blastocyst Cryopreservation: A Case Report.

Ovarian stimulation is used in assisted reproductive technology to help infertile couples achieve pregnancy. Luteal-phase stimulation with progestin-primed ovarian stimulation (PPOS) is a practical approach, as it involves oral medication …

Published: Aug. 17, 2025, midnight
Study on the relationship between endometrial thickness on hCG day in the progestin-primed ovarian stimulation protocols and pregnancy outcomes in frozen-thawed embryo transfer cycles - Frontiers

Study on the relationship between endometrial thickness on hCG day in the progestin-primed ovarian stimulation protocols and pregnancy outcomes in frozen-thawed embryo transfer cycles Frontiers

Published: Aug. 9, 2025, 1:56 a.m.
D-chiro-inositol effectively counteracts endometriosis in a mouse model.

Endometriosis, a common condition affecting 5-10% of women of reproductive age, is the growth of endometrial-like tissue outside the uterus, leading to pain and infertility. Current treatments, such as surgery …

Published: April 11, 2025, midnight
'Ovariostasis' as the main preventive and therapeutic strategy for gynecological pathologies in women of reproductive age.

Ovariostasis is a reversible and temporary suspension of the cyclic ovarian activity, characterized by anovulation and hypogonadotropinemia (low serum concentrations of FSH and LH), which can be observed in case …

Published: April 3, 2025, midnight
Fertility preservation in women with endometriosis: A retrospective non-Inferiority study comparing Dienogest in the PPOS protocol to antagonist and agonist protocols.

Endometriosis is a common pathology that can lead to a decrease in fertility and is therefore a medical indication for preserving fertility. Traditionally, gonadotropin-releasing hormone (GnRH) antagonist and agonist protocols …

Published: April 3, 2025, midnight
In utero exposure to synthetic sex hormones and their multigenerational impact on neurodevelopmental disorders: Endocrine disruptors as neuroendocrine disruptors.

Synthetic sex hormones, estrogens and/or progestogens, have been widely administered without sufficient long-term studies for decades to millions of pregnant women around the world and although most were banned in …

Published: April 1, 2025, midnight
Long-term follow-up of the effect of oral dienogest and dienogest/ethinylestradiol treatment on cell-free DNA levels in patients with deep endometriosis.

Endometriosis is currently considered a systemic inflammatory disease and different non-invasive inflammatory markers, such as cell-free DNA (cfDNA), have recently been evaluated. Hormonal treatments are frequently prescribed as first-line treatments …

Published: March 21, 2025, midnight
The efficacy of progestins in managing pain associated with endometriosis, fibroids and pre-menstrual syndrome: a systematic review.

Alongside being contraceptives, progestins have been investigated as potential anti-inflammatory and analgesic therapies for use in painful gynaecological conditions. This review aims to synthesise evidence pertaining to the efficacy of …

Published: March 11, 2025, midnight
Progestin induced depression in endometriosis.

Published: Feb. 26, 2025, midnight
Non-inferiority study to compare the efficacy of relugolix with dienogest for endometriosis-associated pain and usefulness of administering relugolix prior to dienogest (READY study): study protocol for a multicenter randomized controlled study.

Endometriosis presents as endometrial tissue growths outside the uterine cavity with its major symptoms including dysmenorrhea and infertility. Progestin preparations, such as dienogest, are the first-line therapy for endometriosis symptoms, …

Published: Feb. 6, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!